DK0689836T3 - Spirooxathiolan-quinuclidin- derivat til behandling af xerostomi - Google Patents

Spirooxathiolan-quinuclidin- derivat til behandling af xerostomi

Info

Publication number
DK0689836T3
DK0689836T3 DK95304449T DK95304449T DK0689836T3 DK 0689836 T3 DK0689836 T3 DK 0689836T3 DK 95304449 T DK95304449 T DK 95304449T DK 95304449 T DK95304449 T DK 95304449T DK 0689836 T3 DK0689836 T3 DK 0689836T3
Authority
DK
Denmark
Prior art keywords
salivary gland
alkyl
treatment
xerostomia
therapeutic agent
Prior art date
Application number
DK95304449T
Other languages
Danish (da)
English (en)
Inventor
Harumi Handa
Yasuyoshi Takeshita
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of DK0689836T3 publication Critical patent/DK0689836T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
DK95304449T 1994-06-27 1995-06-22 Spirooxathiolan-quinuclidin- derivat til behandling af xerostomi DK0689836T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6168982A JP2852608B2 (ja) 1994-06-27 1994-06-27 口腔乾燥症治療剤

Publications (1)

Publication Number Publication Date
DK0689836T3 true DK0689836T3 (da) 2002-05-06

Family

ID=15878165

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95304449T DK0689836T3 (da) 1994-06-27 1995-06-22 Spirooxathiolan-quinuclidin- derivat til behandling af xerostomi

Country Status (15)

Country Link
US (1) US5580880A (de)
EP (1) EP0689836B1 (de)
JP (1) JP2852608B2 (de)
KR (1) KR100322042B1 (de)
AT (1) ATE205085T1 (de)
AU (1) AU707236B2 (de)
CA (1) CA2152420A1 (de)
CY (1) CY2290B1 (de)
DE (1) DE69522511T2 (de)
DK (1) DK0689836T3 (de)
ES (1) ES2163474T3 (de)
IL (1) IL114256A (de)
NO (1) NO309454B1 (de)
TW (1) TW401298B (de)
ZA (1) ZA955317B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP4909809B2 (ja) * 1999-03-24 2012-04-04 生化学工業株式会社 人工唾液
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8450487B2 (en) * 2010-06-08 2013-05-28 Apicore, Llc Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
EP3384786B1 (de) 2015-12-04 2022-03-09 San-Ei Gen F.F.I., INC. Verwendung von enzymmodifiziertem isoquercitrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US5078129A (en) * 1987-05-01 1992-01-07 Research Foundation Of State University Of New York Device for stimulating salivation
IL87234A (en) 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US4917674A (en) * 1988-04-04 1990-04-17 Molinoff Henry C Mouth moisturizing device
US4906455A (en) * 1988-04-15 1990-03-06 Wm. Wrigley Jr. Company Method for treating xerostomia employing chewing gum containing relatively insoluble, hydrophobic, food-grade organic acid
US4983378A (en) * 1988-11-22 1991-01-08 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
JP3018494B2 (ja) * 1990-11-30 2000-03-13 ソニー株式会社 特殊効果装置
JP2683783B2 (ja) * 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤

Also Published As

Publication number Publication date
TW401298B (en) 2000-08-11
JP2852608B2 (ja) 1999-02-03
IL114256A0 (en) 1995-10-31
IL114256A (en) 1999-05-09
ATE205085T1 (de) 2001-09-15
US5580880A (en) 1996-12-03
AU707236B2 (en) 1999-07-08
AU2324595A (en) 1996-01-11
ES2163474T3 (es) 2002-02-01
CA2152420A1 (en) 1995-12-28
EP0689836B1 (de) 2001-09-05
NO952561D0 (no) 1995-06-26
EP0689836A1 (de) 1996-01-03
KR960000222A (ko) 1996-01-25
KR100322042B1 (ko) 2002-11-04
NO309454B1 (no) 2001-02-05
DE69522511D1 (de) 2001-10-11
CY2290B1 (en) 2003-07-04
ZA955317B (en) 1996-02-02
JPH0812575A (ja) 1996-01-16
DE69522511T2 (de) 2002-05-16
NO952561L (no) 1995-12-28

Similar Documents

Publication Publication Date Title
DK0689836T3 (da) Spirooxathiolan-quinuclidin- derivat til behandling af xerostomi
ATE45731T1 (de) 3-substituierte 2-oxindole-1-carboxamide, als analgetische und antiinflammatorische mittel verwendet.
FR2692264B1 (fr) Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
OA09334A (fr) "Dérivés d'acides aminés".
BR9814755A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para a preparação de um composto, para inibir a secreção do ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinais, e para o tratamento ou profilaxia de condições que envolvam infecção por helicobacter pylori da mucosa gástrica humana
EE05530B1 (et) Gamma-aminov?ihappe derivaate sisaldavad tahked kompositsioonid ja nende saamise meetod
ATE81459T1 (de) Verwendung von salzen der n-acetylneuraminsaeure zur herstellung eines arzneimittels zum abschwellen der nasenschleimhaut.
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
FI932390A0 (fi) Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning
DE3586935D1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
NO932520L (no) Preparat for helbredelse av sykdommen Sjoegren's syndrom
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE137969T1 (de) Benzimidazolverbindungen als antibiotika gegen campylobacter pylon
ES8606297A1 (es) Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil)-oxialquilamidas
ATE34662T1 (de) Derivate der benzoesaeure, herstellungsverfahren und anwendung in desinfizierenden und konservierenden arzneimitteln.
DE69030502D1 (de) Cephalosporinverbindungen und deren herstellung
IT8621112A1 (it) Derivati dell'acido tiazolidin-4-carbossilico ad attività farmaceutica
ATE42955T1 (de) Phosphorsaeureesterderivate, ihre herstellung und ihre therapeutische anwendung.
ATE40521T1 (de) Verwendung eines substanzgemisches fuer die herstellung eines mittels gegen buergers krankheit.
DE69819002D1 (de) Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln
DE3675291D1 (de) 1-alkyl-ergolinyl-thioharnstoffderivate.
NZ509703A (en) Therapeutic agent comprising spirooxathiolane-quinuclidine for the treatment of dry mouth
ATE95697T1 (de) Uricosuretische zusammensetzung.
ES8703886A1 (es) Procedimiento para la obtencion de n-(diamino-fosfinil)halo-benzamidas